The Lock and Key of Medicine : Monoclonal Antibodies and the Transformation of Healthcare /
Saved in:
| Author / Creator: | Marks, Lara, 1963- author. |
|---|---|
| Imprint: | New Haven [Connecticut] ; London : Yale University Press, [2015] ©2015 |
| Description: | 1 online resource : illustrations |
| Language: | English |
| Subject: | |
| Format: | E-Resource Book |
| URL for this record: | http://pi.lib.uchicago.edu/1001/cat/bib/11675867 |
MARC
| LEADER | 00000cam a2200000Ii 4500 | ||
|---|---|---|---|
| 001 | 11675867 | ||
| 005 | 20210426223505.7 | ||
| 006 | m o d | ||
| 007 | cr cnu|||unuuu | ||
| 008 | 150602t20152015ctua ob 001 0 eng d | ||
| 019 | |a 1058624084 |a 1096218169 | ||
| 020 | |a 9780300213522 |q (electronic bk.) | ||
| 020 | |a 0300213522 |q (electronic bk.) | ||
| 020 | |z 9780300167733 |q (print) | ||
| 020 | |z 0300167733 | ||
| 035 | |a (OCoLC)910553652 |z (OCoLC)1058624084 |z (OCoLC)1096218169 | ||
| 035 | 9 | |a (OCLCCM-CC)910553652 | |
| 040 | |a N$T |b eng |e rda |e pn |c N$T |d N$T |d IDEBK |d E7B |d YDXCP |d CDX |d OCLCF |d EBLCP |d OH1 |d KSU |d NRC |d OCLCO |d OCLCQ |d OCLCA |d BAL |d BUF |d OCLCO |d WRM |d OCLCO |d GILDS |d OCLCO |d AGLDB |d OCLCO |d IGB |d OCLCO |d INT |d AUW |d BTN |d MHW |d INTCL |d SNK |d OCLCO |d AU@ |d OCLCQ |d A6Q |d G3B |d S8I |d S8J |d STF |d JBG |d D6H |d M8D |d OCLCO |d OCLCQ |d OCLCA |d DEGRU | ||
| 049 | |a MAIN | ||
| 050 | 4 | |a QR186.85 | |
| 060 | 4 | |a QW 575.5.A6 | |
| 072 | 7 | |a HEA |x 039000 |2 bisacsh | |
| 072 | 7 | |a MED |x 014000 |2 bisacsh | |
| 072 | 7 | |a MED |x 022000 |2 bisacsh | |
| 072 | 7 | |a MED |x 112000 |2 bisacsh | |
| 072 | 7 | |a MED |x 045000 |2 bisacsh | |
| 100 | 1 | |a Marks, Lara, |d 1963- |e author. |0 http://id.loc.gov/authorities/names/n92800427 | |
| 245 | 1 | 4 | |a The Lock and Key of Medicine : |b Monoclonal Antibodies and the Transformation of Healthcare / |c Lara V. Marks. |
| 264 | 1 | |a New Haven [Connecticut] ; |a London : |b Yale University Press, |c [2015] | |
| 264 | 4 | |c ©2015 | |
| 300 | |a 1 online resource : |b illustrations | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 505 | 0 | |a Illustrations -- Preface -- Acknowledgments -- Abbreviations -- Hunting for the Elusive "Magic Bullet" -- A Hesitant Start Patents, Politics, and Process -- Breakthroughs at the Bench -- The First Medical Applications -- Joy, Disappointment, Determination Early Clinical Tests -- The Wild West of Antibody Commercialization -- The Challenge of Monoclonal Antibody Drugs -- Antibody Engineering: A Renaissance for Mab Therapeutics -- Blockbuster Mab Drugs -- A Quiet Revolution: The Legacy of Monoclonal Antibodies -- Notes -- Glossary -- Bibliography -- Index. | |
| 588 | 0 | |a Vendor-supplied metadata. | |
| 504 | |a Includes bibliographical references and index. | ||
| 520 | |a The untold story of monoclonal antibodies-the molecular heroes of biotechnology that revolutionized the diagnosis and treatment of more than fifty major diseases This book is the first to tell the extraordinary yet unheralded history of monoclonal antibodies. Often referred to as Mabs, they are unfamiliar to most nonscientists, yet these microscopic protein molecules are everywhere, quietly shaping our lives and healthcare. Discovered in the mid-1970s in the laboratory where Watson and Crick had earlier unveiled the structure of DNA, Mabs have radically changed understandings of the pathways of disease. They have enabled faster, cheaper, and more accurate clinical diagnostic testing on a vast scale. And they have played a fundamental role in pharmaceutical innovation, leading to such developments as recombinant interferon and insulin, and personalized drug therapies such as Herceptin. Today Mabs constitute six of the world's top ten blockbuster drugs and make up a third of new introduced treatments. Lara V. Marks recounts the risks and opposition that a daring handful of individuals faced while discovering and developing Mabs, and she addresses the related scientific, medical, technological, business, and social challenges that arose. She offers a saga of entrepreneurs whose persistence and creativity ultimately changed the healthcare landscape and brought untold relief to millions of patients. Even so, as Marks shows, controversies over Mabs remain, and she examines current debates over the costs and effectiveness of these innovative drugs. | ||
| 650 | 0 | |a Monoclonal antibodies. |0 http://id.loc.gov/authorities/subjects/sh85005650 | |
| 650 | 2 | |a Antibodies, Monoclonal |x therapeutic use. | |
| 650 | 7 | |a HEALTH & FITNESS |x Diseases |x General. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Clinical Medicine. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Diseases. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Evidence-Based Medicine. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Internal Medicine. |2 bisacsh | |
| 650 | 7 | |a Monoclonal antibodies. |2 fast |0 (OCoLC)fst01025547 | |
| 655 | 4 | |a Electronic books. | |
| 903 | |a HeVa | ||
| 929 | |a oclccm | ||
| 999 | f | f | |i 4b992248-8d18-594c-ad4b-17aa567a063a |s f1637443-ee61-567a-8d5b-263ecd99c5a8 |
| 928 | |t Library of Congress classification |a QR186.85 |l Online |c UC-FullText |u https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=e000xna&AN=1000448 |z eBooks on EBSCOhost |g ebooks |i 12426431 | ||